- Home
- IMUX vs RDZN Comparison
IMUX vs RDZN Comparison
Compare IMUX & RDZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMUX
- RDZN
- Stock Information
- Founded
- IMUX 2016
- RDZN 2015
- Country
- IMUX United States
- RDZN United States
- Employees
- IMUX N/A
- RDZN N/A
- Industry
- IMUX Biotechnology: Pharmaceutical Preparations
- RDZN Blank Checks
- Sector
- IMUX Health Care
- RDZN Finance
- Exchange
- IMUX Nasdaq
- RDZN Nasdaq
- Market Cap
- IMUX 94.9M
- RDZN 79.4M
- IPO Year
- IMUX N/A
- RDZN N/A
- Fundamental
- Price
- IMUX $1.01
- RDZN $0.78
- Analyst Decision
- IMUX Strong Buy
- RDZN Strong Buy
- Analyst Count
- IMUX 6
- RDZN 2
- Target Price
- IMUX $13.20
- RDZN $5.00
- AVG Volume (30 Days)
- IMUX 1.3M
- RDZN 243.1K
- Earning Date
- IMUX 05-20-2025
- RDZN 07-01-2025
- Dividend Yield
- IMUX N/A
- RDZN N/A
- EPS Growth
- IMUX N/A
- RDZN N/A
- EPS
- IMUX N/A
- RDZN N/A
- Revenue
- IMUX N/A
- RDZN $42,893,256.00
- Revenue This Year
- IMUX N/A
- RDZN $4.52
- Revenue Next Year
- IMUX N/A
- RDZN $53.72
- P/E Ratio
- IMUX N/A
- RDZN N/A
- Revenue Growth
- IMUX N/A
- RDZN 2.79
- 52 Week Low
- IMUX $0.83
- RDZN $0.71
- 52 Week High
- IMUX $2.11
- RDZN $4.43
- Technical
- Relative Strength Index (RSI)
- IMUX 46.64
- RDZN 41.34
- Support Level
- IMUX $0.95
- RDZN $0.68
- Resistance Level
- IMUX $1.22
- RDZN $1.01
- Average True Range (ATR)
- IMUX 0.12
- RDZN 0.11
- MACD
- IMUX -0.01
- RDZN -0.01
- Stochastic Oscillator
- IMUX 16.67
- RDZN 31.94
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
About RDZN Roadzen Inc.
Roadzen Inc is an insurance technology company on a mission to transform global auto insurance powered by advanced AI. Its clients comprise major insurers, fleets, and carmakers to small fleets, brokers, and insurance agents that use Roadzen's technology to build new products, sell insurance, process claims, and improve road safety. The company's work in telematics and computer vision has earned recognition as an AI innovator by publications such as Forbes, Fortune, and Financial Express.